panitumumab,dexamethasone,bortezomib,bevacizumab,lenalidomide,trastuzumab deruxtecan
astrazeneca,amgen,takeda,daiichi sankyo,roche
['mbc', 'determination', 'sarcoma', '#gi', 'crcsm', 'bcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'mmsm', 'breast', 'destinybreast04', 'paradigm', 'reecur', 'gism']
#asco22 #plenarysession summary 1. #destinybreast04: tdxd in low her2 mbc
2. #paradigm: pan + mfolfox6 vs bev + mfolfox6 in mcrc
3. #reecur: topotecan, cyclophos &amp; hd ifos in ewing #sarcoma
4. #determination: rvd +/- asct + rev in myeloma
#bcsm #crcsm #gism #mmsm 1/5
Practice changing #Oncology news from #CommunityOncologists perspective w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @GuthrieClinic. Views are our own.